Adzenys Xr-odt Patent Expiration

Adzenys Xr-odt is a drug owned by Neos Therapeutics. It is protected by 5 US drug patents filed from 2016 to 2024 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Jun 28, 2032. Details of Adzenys Xr-odt's patents and their expiration are given in the table below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8709491 Composition comprising a mixture of dextro- and levo-amphetamines complexed with ion-exchange resin particles to form drug resin particles
Jun, 2032

(7 years from now)

Active
US9017731 Composition comprising a mixture of dextro- and levo-amphetamines complexed with ion-exchange resin particles to form drug resin particles
Jun, 2032

(7 years from now)

Active
US9265737 Pharmaceutical composition comprising amphetamines complexed with ion-exchange resin particles
Jun, 2032

(7 years from now)

Active
US9839619 Method for treating ADD or ADHD comprising administering amphetamine complexed with ion-exchange resin particles
Jun, 2032

(7 years from now)

Active
US8840924 Compositions and methods of making rapidly dissolving ionically masked formulations
Apr, 2026

(1 year, 6 months from now)

Active


A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Adzenys Xr-odt's patents.

Given below is the list of recent legal activities going on the following patents of Adzenys Xr-odt.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 8th Yr, Small Entity 21 Oct, 2022 US9017731 (Litigated)
Payment of Maintenance Fee, 4th Yr, Small Entity 03 Jun, 2021 US9839619
Email Notification 09 Apr, 2020 US9839619
Change in Power of Attorney (May Include Associate POA) 09 Apr, 2020 US9839619
Change in Power of Attorney (May Include Associate POA) 09 Apr, 2020 US9017731 (Litigated)
Email Notification 09 Apr, 2020 US9017731 (Litigated)
Correspondence Address Change 08 Apr, 2020 US9839619
Correspondence Address Change 08 Apr, 2020 US9017731 (Litigated)
Payment of Maintenance Fee, 4th Yr, Small Entity 29 Oct, 2018 US9017731 (Litigated)
Patent Issue Date Used in PTA Calculation 12 Dec, 2017 US9839619

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

US patents provide insights into the exclusivity only within the United States, but Adzenys Xr-odt is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Adzenys Xr-odt's family patents as well as insights into ongoing legal events on those patents.

Adzenys Xr-odt's Family Patents

Adzenys Xr-odt has patent protection in a total of 2 countries. It has a significant patent presence in the US with 94.4% of its patents being US patents. Click below to unlock the full patent family tree for Adzenys Xr-odt.

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


Generic Launch

Generic Release Date:

Adzenys Xr-odt's generic launch date based on the expiry of its last outstanding patent is estimated to be Jun 28, 2032 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Adzenys Xr-odt Generics:

Amphetamine is the generic name for the brand Adzenys Xr-odt. 1 company has already filed for the generic of Adzenys Xr-odt. Check out the entire list of companies who have already received approval for Adzenys Xr-odt's generic

How can I launch a generic of Adzenys Xr-odt before its drug patent expiration? :

You can seek FDA approval to launch a generic drug before the expiration of Adzenys Xr-odt's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the Adzenys Xr-odt's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Given below are the details of the already filed Para IV certificates on Adzenys Xr-odt -

Strength Submission Date ANDA(s) Filed First applicant approval Last patent expiry 180 day status
3.1 mg, 6.3 mg, 9.4 mg, 12.5 mg, 15.7 mg, 18.8 mg 10 May, 2016 1 22 Jun, 2023 28 Jan, 2032 Deferred

Alternative Brands for Adzenys Xr-odt

There are several other brand drugs using the same active ingredient (Amphetamine) as Adzenys Xr-odt. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.


Apart from brand drugs containing the same ingredient, some generics have also been filed for Amphetamine, Adzenys Xr-odt's active ingredient. Check the complete list of approved generic manufacturers for Adzenys Xr-odt





About Adzenys Xr-odt

Adzenys Xr-Odt is a drug owned by Neos Therapeutics. Adzenys Xr-Odt uses Amphetamine as an active ingredient. Adzenys Xr-Odt was launched by Neos Theraps in 2016.

Approval Date:

Adzenys Xr-odt was approved by FDA for market use on 27 January, 2016.

Active Ingredient:

Adzenys Xr-odt uses Amphetamine as the active ingredient. Check out other Drugs and Companies using Amphetamine ingredient

Dosage:

Adzenys Xr-odt is available in tablet, orally disintegrating, extended release form for oral use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
EQ 3.1MG BASE TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE Prescription ORAL
EQ 15.7MG BASE TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE Prescription ORAL
EQ 6.3MG BASE TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE Prescription ORAL
EQ 12.5MG BASE TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE Prescription ORAL
EQ 18.8MG BASE TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE Prescription ORAL
EQ 9.4MG BASE TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE Prescription ORAL